Board of Directors

Carl Borrebaeck (1948), Chairman

Professor Carl Borrebaeck is a successful serial entrepreneur, having co-founded Immunovia AB, Senzagen AB (SENZA; Nasdaq First North), BioInvent International AB (BINV: Stockholm) and Alligator BioScience AB (ATORX; Nasdaq Stockholm). Prof. Borrebaeck is a 2009 recipient of the AkzoNobel Science Award and was awarded the 2012 Gold Medal from the Royal Academy of Engineering Sciences in recognition of his ground-breaking research regarding biomarkers. In 2017 he was designated as the Biotech builder of the Year for his entrepreneurship. In addition, Prof. Borrebaeck is previously the Vice-President of Lund University, Sweden (responsible for its Innovation systems); and currently Director of CREATE Health, a Translational Cancer Center; and previously chairman of the Department of Immunotechnology. Carl Borrebaeck is also a founding mentor for NOME (Nordic Mentor Network for Entrepreneurship).

Immunovia has entered into an agreement with CB Ocean Capital AB regarding services to be provided by Carl Borrebaeck. Carl Borrebaeck shall provide services aimed at providing scientific and strategical support to the Company, for example at scientific presentations and conferences. The services provided do not include tasks that belongs to his board assignment. According to the agreement, CB Ocean Capital AB receives a remuneration of SEK 31,500 each quarter, excluding social fees and VAT. The agreement is valid from 1 January 2018 until further notice, with a mutual three-month notice period.

Current board appointments: Chairman of the Board of Senzagen AB and Ocean Capital AB. Member of the Board of Alligator Bioscience AB, Clinical Laserthermia Systems AB and Scandion A/S. Carl Borrebaeck is also partner of Immunova Handelsbolag.

Completed appointments (last five years): Carl Borrebaeck has been Chairman of the Board of LU Innovation System AB. He has been Member of the Board of Atlas Therapeutics AB, BioInvent International AB, LU Holdings AB, Medicon Village Fastighets AB and WntResearch AB. He has also been Deputy Director of Endo Medical AB.

Ann-Christine Sundell (1964)

Ann-Christine Sundell has a MSc in biochemistry and more than 30 years of experience from the medical device industry, she has held various global positions. For 10 years she served as president for Genetic Screening, one of five strategic business areas with over 1500 employees worldwide within PerkinElmer, one of the world’s largest Life Science companies.

Ann-Christine has strategic and operational experience from areas where Immunovia is active such as Sales & Marketing, R&D, production, quality and compliance.

Current board appointments: Chairman of the Board of Oy Medix Biochemica Ab and Serres Oy. Board Member of Ab Archipelagia Golf Oy, BluePrint Genetics Oy, Ledil Group OY, Ledil Oy, Minervastiftelsen, Oy Medix Ab, Raisio Oyj and Revenio Group Oyj. Committee Member of Raisio Oyj’s Research Foundation and holder of AConsult.

Completed appointments (last five years): Chairman of the Board of Oy Medix Biochemica Ab. Board member of the Minervastiftelsen, Oy Medix Ab, Vanadis Ab and Zymonostics ApS.

Hans Johansson (1954)

Hans Johansson has a MSc in Chemical Engineering and excessive experience and a wide network from his previous positions in Life Science and Diagnostics companies, lately as VP, Head of Companion Diagnostics at ThermoFisher Inc Speciality Diagnostics Group.

Hans Johansson was also a former VP of Global Marketing and Commercial Development within the same company but at the ImmunoDiagnostics division and earlier VP, Head of the Laboratory Business Unit at Pharmacia Biotechnology.

Hans Johansson has also been an active entrepreneur as CEO/Boardmember in the life science sector. Altogether, he has 30 years of experience from global business development and commercialization of biotechnical and diagnostic innovations.

Current board appointments: Chairman of the Board of Doloradix AB and Myrtila AB. He has been a Board Member of Single Technologies AB and Uppsala Innovation Centre AB.

Completed appointments (last five years): He has been Deputy Director of Duvbo Affärskonsult AB.

Åsa Hedin (1962)

Åsa Hedin has a degree in biophysics from the University of Minnesota and has a bachelor’s degree in physics from Gustavus Adolphus College. Åsa Hedin also has a Diploma Pro Board work, M Berglund Board value.

Current appointments: Åsa Hedin is a Board Member of CellaVision AB, C-Rad AB, E. Öhman J:or Fonder AB, Fingerprint Cards AB, HerMed Group Holding AB, Nolato Aktiebolag and Tobii AB.

Completed assignments (last five years): Åsa Hedin has been Chairman of the Board of Elekta Oy and Member of the Board of Sensavis AB and Svenska rymdaktiebolaget. She has also been a Board Member and CEO of Elekta Instrument AB.

Ann-Christin Malmborg Hager (1965)

Ann-Christin Malmborg Hager is a Civil Engineer in Chemical Technology and has a PhD in immunoassay technology from Lunds tekniska högskola. Ann-Christin Malmborg Hager is the CEO of SenzaGen AB, which was introduced to the Nasdaq First North list in September, 2017.

Ann-Christin Malmborg Hager has previously been CEO of several start-up companies including Cantargia, Diaprost, XImmune and Investment Director. In addition, Ann-Christin Malmborg Hager has experience in Business Development, for example from Alligator Bioscience AB.

Current appointments: Ann-Christin Malmborg Hager has been a Board Member of Avena Partners AB, Diaprost AB and Hager Consulting AB. She is CEO of SenzaGen AB.

Completed appointments (last five years): Ann-Christin Malmborg Hager has been a Board Member of bulb intelligence AB and Cantargia AB and a CEO of Sista versen 26366 AB.


Subscribe to receive press releases and reports via email
To start your subscription you need to activate your e-mail address by clicking the link in the email that is sent to you after you have submitted this form.

Press releases
Financial reports